Search filters

List of works by Kena A Swanson

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

scientific article published in 2021

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses

scientific article published on 30 September 2020

Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine

preprint

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

scientific article published on 19 January 2021

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

scientific article

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

preprint

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

scientific article published on 12 August 2020

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

correction of a scholarly article

Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

correction of a scholarly article

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

scientific article published on 20 August 2020

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine ⬇️

scientific article published on 10 December 2020

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

scientific article published on 14 October 2020

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

scientific article

Paulina is supported by:

About Paulina

Help